Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders.

Rodolfo Sacco ¹, Tomotaka Tanaka, Takayuki Yamamoto, Giampaolo Bresci, Abbi R Saniabadi, Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):327-33.

The authors’ view is that in patients with UC, there is an evolving scope for therapeutic opportunity based on taking away the sources of inflammatory cytokines, also considering the favorable safety profile of GMA.

https://pubmed.ncbi.nlm.nih.gov/25160857/